Cyclic AMP‐hydrolyzing phosphodiesterase inhibitors potentiate statin‐induced cancer cell death
Dipyridamole, an antiplatelet drug, has been shown to synergize with statins to induce cancer cell‐specific apoptosis. However, given the polypharmacology of dipyridamole, the mechanism by which it potentiates statin‐induced apoptosis remains unclear. Here, we applied a pharmacological approach to i...
Main Authors: | Joseph Longo, Aleksandra A. Pandyra, Paweł Stachura, Mark D. Minden, Aaron D. Schimmer, Linda Z. Penn |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12775 |
Similar Items
-
The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins
by: Huanbiao Mo, et al.
Published: (2019-01-01) -
Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review
by: Salvatore Santo Signorelli, et al.
Published: (2020-08-01) -
Effects of phosphodiesterase 3A modulation on murine cerebral microhemorrhages
by: Rachita K. Sumbria, et al.
Published: (2017-06-01) -
The Potential Use of Metformin, Dipyridamole, N-Acetylcysteine and Statins as Adjunctive Therapy for Systemic Lupus Erythematosus
by: Marcus Kai Xuan Tan, et al.
Published: (2019-04-01) -
Effects of phosphodiesterase inhibitors on secretions of human monokines
by: Yuji Suda, et al.
Published: (1998-01-01)